Literature DB >> 27790848

Successful treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis.

Irene Russo1, Serena Miotto1, Anna Colpo2, Piero Marson2, Tiziana Tison2, Anna Ferrazzi1, Mauro Alaibac1.   

Abstract

Pyoderma gangrenosum is a neutrophilic dermatosis clinically characterised by the presence of painful skin ulcerations with erythematous and undetermined borders and histologically by the presence of neutrophilic infiltrates in the dermis. Granulocyte and monocyte adsorption apheresis, also called granulocytapheresis, is a therapeutic strategy for extracorporeal immunomodulation that selectively removes activated granulocytes and monocytes/macrophages from the peripheral blood. Here, we report a case of a 73-year-old patient affected by a severe form of pyoderma gangrenosum presenting with multiple painful ulcers and pustules on his trunk and extremities. The disease was resistant to high doses of methylprednisolone and methotrexate and successfully treated by granulocyte and monocyte adsorption apheresis. To the best of our knowledge, this is the first report on the efficacy of granulocyte and monocyte adsorption apheresis in pyoderma gangrenosum in Europe.
© 2016 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  Granulocyte and monocyte adsorption apheresis; Neutrophilic dermatosis; Pyoderma gangrenosum

Mesh:

Year:  2016        PMID: 27790848      PMCID: PMC7949586          DOI: 10.1111/iwj.12684

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  22 in total

Review 1.  Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes.

Authors:  Abby R Saniabadi; Hiroyuki Hanai; Ken Takeuchi; Kazuo Umemura; Mitsuyoshi Nakashima; Taro Adachi; Chikako Shima; Ingvar Bjarnason; Robert Lofberg
Journal:  Ther Apher Dial       Date:  2003-02       Impact factor: 1.762

Review 2.  The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.

Authors:  H Hanai; Y Takeda; M Eberhardson; R Gruber; A R Saniabadi; O Winqvist; R Lofberg
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

3.  Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis.

Authors:  Tamihiro Kawakami; Masahide Yamazaki; Yoshinao Soma
Journal:  Am J Gastroenterol       Date:  2009-09       Impact factor: 10.864

4.  Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease.

Authors:  K Sawada; K Ohnishi; T Kosaka; S Fukui; M Yamamura; K Amano; M Satomi; T Shimoyama
Journal:  J Gastroenterol       Date:  1995-11       Impact factor: 7.527

5.  Pyoderma Gangrenosum with Ulcerative Colitis Successfully Treated by the Combination of Granulocyte and Monocyte Adsorption Apheresis and Corticosteroids.

Authors:  Masashi Ohno; Shigeki Koyama; Mariko Ohara; Kazumi Shimamoto; Yu Kobayashi; Fumiyasu Nakamura; Kazuki Mitsuru; Akira Andoh
Journal:  Intern Med       Date:  2016-01-01       Impact factor: 1.271

Review 6.  Etiology and management of pyoderma gangrenosum: a comprehensive review.

Authors:  Iris Ahronowitz; Joanna Harp; Kanade Shinkai
Journal:  Am J Clin Dermatol       Date:  2012-06-01       Impact factor: 7.403

7.  Treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis.

Authors:  Takuro Kanekura; Koichi Kawahara; Ikuro Maruyama; Tamotsu Kanzaki
Journal:  Ther Apher Dial       Date:  2005-08       Impact factor: 1.762

8.  Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum.

Authors:  Mariko Seishima; Yoko Mizutani; Yoshinao Shibuya; Chikako Nagasawa; Takahiko Aoki
Journal:  Ther Apher Dial       Date:  2007-06       Impact factor: 1.762

9.  Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study.

Authors:  Hiroyuki Hanai; Fumitoshi Watanabe; Ken Takeuchi; Takayuki Iida; Masami Yamada; Yasushi Iwaoka; Abby Saniabadi; Isao Matsushita; Yoshihiko Sato; Kotaro Tozawa; Hajime Arai; Takahisa Furuta; Ken Sugimoto; Ingvar Bjarnason
Journal:  Clin Gastroenterol Hepatol       Date:  2003-01       Impact factor: 11.382

10.  A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis.

Authors:  Keiko Okuma; Kouichi Mitsuishi; Toshio Hasegawa; Hitoshi Tsuchihashi; Hideoki Ogawa; Shigaku Ikeda
Journal:  Ther Apher Dial       Date:  2007-10       Impact factor: 1.762

View more
  5 in total

Review 1.  Use of granulocyte and monocyte adsorption apheresis in dermatology (Review).

Authors:  Laura Gnesotto; Guido Mioso; Mauro Alaibac
Journal:  Exp Ther Med       Date:  2022-06-24       Impact factor: 2.751

Review 2.  Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current status.

Authors:  Kentaro Tominaga; Kenya Kamimura; Hiroki Sato; Masayoshi Ko; Yuzo Kawata; Takeshi Mizusawa; Junji Yokoyama; Shuji Terai
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

3.  Peritoneal Dialysis Exit Site Pyoderma Gangrenosum: A Case Report.

Authors:  Salman Anwar; Karen Holfeld; Bhanu Prasad
Journal:  Case Rep Nephrol Dial       Date:  2018-11-14

Review 4.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233

5.  Rapidly Progressing Aseptic Abscesses in a Patient with Ulcerative Colitis.

Authors:  Yoshiharu Yamaguchi; Marie Nakagawa; Shoko Nakagawa; Kazuhiro Nagao; Satoshi Inoue; Tomoya Sugiyama; Shinya Izawa; Yasutaka Hijikata; Masahide Ebi; Yasushi Funaki; Naotaka Ogasawara; Makoto Sasaki; Kunio Kasugai
Journal:  Intern Med       Date:  2020-09-30       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.